
    
      This clinical trail was a multicenter, parallel, randomized, double-blind, placebo-controlled
      study led by Professor Liu Chunfeng from the Second Affiliated Hospital of Suzhou University
      which consisted of 15 sub-centers with a total of 180 subjects.

      This clinical study is divided into two phases:

      The first stage: double-blind period, 24 weeks. Three queues containing idebenone 180
      mg/d,360 mg/d and placebo.

      The second stage: open label extension period, 24 weeks. All enrolled participants continued
      to take idebenone 180 mg/d to study the long-term effects of idebenone.
    
  